nach oben

European Radiology

Erschienen in:

01.02.2006 | Urogenital

Prostate MR imaging at high-field strength: evolution or revolution?

verfasst von: Olivier Rouvière, Robert P. Hartman, Denis Lyonnet

Erschienen in: European Radiology | Ausgabe 2/2006

Einloggen, um Zugang zu erhalten

Abstract

As 3 T MR scanners become more available, body imaging at high field strength is becoming the subject of intensive research. However, little has been published on prostate imaging at 3 T. Will high-field imaging dramatically increase our ability to depict and stage prostate cancer? This paper will address this question by reviewing the advantages and drawbacks of body imaging at 3 T and the current limitations of prostate imaging at 1.5 T, and by detailing the preliminary results of prostate 3 T MRI. Even if slight adjustments of imaging protocols are necessary for taking into account the changes in T1 and T2 relaxation times at 3 T, tissue contrast in T2-weighted (T2w) imaging seems similar at 1.5 T and 3 T. Therefore, significant improvement in cancer depiction in T2w imaging is not expected. However, increased spatial resolution due to increased signal-to-noise ratio (SNR) may improve the detection of minimal capsular invasion. Higher field strength should provide increased spectral and spatial resolution for spectroscopic imaging, but new pulse sequences will have to be designed for overcoming field inhomogeneities and citrate J-modulation issues. Finally, dynamic contrast-enhanced MRI is the method of imaging that is the most likely to benefit from the increased SNR, with a significantly better trade-off between temporal and spatial resolution.

Schick F (2005) Whole body MRI at high field: technical limits and clinical potential. Eur Radiol 15:946–959CrossRefPubMed

Takahashi M, Uematsu H, Hatabu H (2003) MR imaging at high magnetic fields. Eur J Radiol 46:45–52CrossRefPubMed

Uematsu H, Takahashi M, Dougherty L, Hatabu H (2004) High field body MR imaging preliminary experiences. J Clin Imaging 28:159–162CrossRef

McGee KP, Debbins JP, Boskamp EB, Blawat L, Angelos L, King KF (2004) Cardiac magnetic resonance parallel imaging at 3.0 Tesla: technical feasibility and advantages. J Magn Reson Imaging 19:291–297CrossRefPubMed

Kim HW, Buckley DL, Peterson DM, Duenseing GR, Caserta J, Fitzsimmons J, Blackband SJ (2003) In Vivo prostate magnetic resonance imaging and magnetic resonance spectroscopy at 3 Tesla using transceive pelvic phased array coil: preliminary results. Invest Radiol 38:443–451CrossRefPubMed

Morakkabati-Spitz N, Gieseke J, Kuhl C, Lutterbey G, Von Falkenhausen M, Traeber F, Zivanovic O, Schild HH (2005) 3.0-T high-field magnetic resonance imaging of the female pelvis: preliminary experiences. Eur Radiol 15:639–644CrossRefPubMed

De Bazelaire CMJ, Duhamel GD, Rofsky NM, Alsop DC (2004) MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results. Radiology 230:652–659PubMed

Duewell SH, Ceckler TL, Ong K, Wen H, Jaffer FA, Chesnick SA, Balaban RS (1995) Musculoskeletal MR imaging at 4 T and at 1.5 T: comparison of relaxation times and image contrast. Radiology 196:551–555PubMed

Jezzard P, Duewell S, Balaban RS (1996) MR relaxation times in human brain: measurement at 4 T. Radiology 199:773–779PubMed

10.

Yacoub E, Shmuel A, Pfeuffer J, Van De Moortele PF, Adriany G, Andersen P, Vaughan JT, Merkle H, Ugurbil K, Hu X (2001) Imaging brain function in humans at 7 Tesla. Magn Reson Med 45:588–594CrossRefPubMed

11.

Silvennoinen MJ, Clingman CS, Golay X, Kauppinen RA, Van Zijl PC (2003) Comparison of the dependence of blood R2 and R2* on oxygen saturation at 1.5 and 4.7 Tesla. Magn Reson Med 49:47–60CrossRefPubMed

12.

Frayne R, Goodyear BG, Dickhoff P, Lauzon ML, Sevick RJ (2003) Magnetic resonance imaging at 3.0 Tesla: challenges and advantages in neurological imaging. Invest Radiol 38:385–402CrossRefPubMed

13.

Hinton DP, Wald LL, Pitts J, Schmitt F (2003) Comparison of cardiac MRI on 1.5 and 3.0 Tesla clinical whole body systems. Invest Radiol 38:436–442CrossRefPubMed

14.

Nayak KS, Cunningham CH, Santos JM, Pauly JM (2004) Real-time cardia MRI at 3 Tesla. Magn Reson Med 51:655–660CrossRefPubMed

15.

Masi JN, Sell CA, Phan C, Han E, Newitt D, Steinbach L, Majumdar S, Link TM (2005) Cartilage MR imaging at 3.0 versus that at 1.5 T: preliminary results in a porcine model. Radiology 236:140–150PubMed

16.

Engelbrecht MR, Jager GJ, Severens JL (2001) Patient selection for magnetic resonance imaging of prostate cancer. Eur Urol 40:300–307CrossRefPubMed

17.

Engelbrecht MR, Jager GJ, Laheij RJ, Verbeek AL, Van Lier HJ, Barentsz JO (2002) Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 12:2294–2302PubMed

18.

Jager GJ, Severens JL, Thornbury JR, de la Rosette JJMCH, Ruijs SHJ, Barentsz JO (2000) Prostate cancer staging: Should MR imaging be used? A decision analytic approach. Radiology 215:445–451PubMed

19.

Gelet A, Chapelon JY, Bouvier R, Rouvière O, Lyonnet D, Dubernard JM (2001) Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. Eur Urol 40:124–129CrossRefPubMed

20.

Rouvière O, Valette O, Grivolat S, Colin-Pangaud C, Bouvier R, Chapelon JY, Gelet A, Lyonnet D (2004) Recurrent prostate cancer after external-beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor correlation with biopsy findings. Urology 63:922–927CrossRefPubMed

21.

Beerlage HP, Thuroff S, Madersbacher S, Zlotta AR, Aus G, De Reijke Rosette JJ (2000) Current status of minimally invasive treatment options for localized carcinoma. Eur Urol 37:2–13CrossRefPubMed

22.

Zelefsky MJ (2004) Three-dimensional conformal brachytherapy for prostate cancer. Curr Urol Rep 5:173–178PubMed

23.

Perrotti M, Han KR, Epstein RE, Kennedy EC, Rabbani F, Badani K, Pantuck AJ, Weiss RE, Cummings KB (1999) Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostatic biopsy: a pilot study. J Urol 162:1314–1317CrossRefPubMed

24.

Yuen JSP, Thng CH, Tan PH, Khin LW, Phee SJL, Xiao D, Lau WKO, Ng WS, Cheng CWS (2004) Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol 171:1482–1486CrossRefPubMed

25.

Jager GJ, Ruijter ETG, Van de Kaa CA, de la Rosette JJMCH, Oosterhof GON, Thornbury JR, Barentsz JO (1996) Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. Am J Roentgenol 166:845–852

26.

Quinn SF, Franzini DA, Demlow TA, Rosencrantz DR, Kim J, Hanna RM, Szumowski J (1994) MR imaging of prostate cancer with endorectal surface coil technique: correlation with whole-mount specimens. Radiology 190:323–327

27.

Coakley FV, Kurhanewicz J, Lu Y, Jones KD, Swanson MG, Carroll PR, Hricak H (2002) Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 223:91–97PubMed

28.

Kurhanewicz J, Vigneron DB, Males RG, Swanson MG, Yu KK, Hricak H (2000) The prostate: MR imaging and spectrosopy. Radiol Clin North Am 38:115–138CrossRefPubMed

29.

Scheenen TWJ, Klomp DWJ, Röll SA, Fütterer JJ, Barentsz JO, Heerschap A (2004) Fast acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate. Magn Reson Med 52:80–88CrossRefPubMed

30.

Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, Zaloudek CJ, Nelson SJ, Carroll PR, Kurhanewicz J (1999) Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 213:473–480PubMed

31.

Kaji Y, Kurhanewicz J, Hricak H, Sokolov DL, Huang LR, Nelson SJ, Vigneron DB (1998) Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging. Radiology 206:785–790PubMed

32.

Dhingsa R, Qayyum A, Coakley FV, Lu Y, Jones KD, Swanson MG, Carroll PR, Hricak H, Kurhanewicz J (2004) Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. Radiology 230:215–220PubMed

33.

Chelsky MJ, Schnall MD, Seidmon EJ, Pollack HM (1993) Use of endorectal surface coil magnetic resonance imaging for local staging of prostate cancer. J Urol 150:391–395PubMed

34.

Tempany CM, Zhou X, Zerhouni EA, Rifkin MD, Quint LE, Piccoli CW, Ellis JH, McNeil BJ (1994) Staging of prostate cancer: results of radiology diagnostic oncology group project comparison of three MR imaging techniques. Radiology 192:47–54

35.

Outwater EK, Petersen RO, Siegelman ES, Gomella LG, Chernesky CE, Mitchell DG (1994) Prostate carcinoma: assessment of diagnostic criteria for capsular penetration on endorectal coil MR images. Radiology 193:333–339PubMed

36.

Harris RD, Schned AR, Heaney JA (1995) Staging of prostate cancer with endorectal MR imaging: lessons from a learning curve. Radiographics 15:813–829PubMed

37.

Chefchaouni MC, Flam T, Cornud F, Thiounn N, Belin X, Deslignères S, Zerbib M, Moreau JL, Debré B (1996) Résultats de l’IRM endo-rectale dans la stadification locale du cancer de la prostate. J Urol 102:51–55

38.

Presti JC, Hricak H, Narayan PA, Shinohara K, White S, Carroll PR (1996) Local staging of prostatic carcinoma: comparison of transrectal sonography and endorectal MR imaging. Am J Roentgenol 166:103–108

39.

Yu KK, Hricak H, Alagappan R, Chernoff DM, Bacchetti P, Zaloudek CJ (1997) Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. Radiology 202:697–702

40.

Yu KK, Scheidler J, Hricak H (1999) Prostate cancer: prediction of extracapsular extension by endorectal MR imaging and 3D 1H-MR spectroscopic imaging. Radiology 213:481–488PubMed

41.

Bates TS, Gillatt DA, Cavanagh PM, Speakman M (1997) A comparison of endorectal magnetic resonance imaging and transrectal ultrasonography in the local staging of prostate cancer with histopathological correlation. Br J Urol 79:927–932PubMed

42.

Ikonen S, Kärkkäinen P, Kivisaari L, Salo JO, Taari K, Vehmas T, Tervahartiala P, Rannikko S (2001) Endorectal magnetic resonance imaging of prostatic cancer: comparison between fat-suppressed T2-weighted fast spin echo and three-dimensional dual-echo, steady-state sequences. Eur Radiol 11:236–241CrossRefPubMed

43.

Cornud F, Flam T, Chauveinc L, Hamida K, Chrétien Y, Vieillefond A, Hélénon O, Moreau JF (2002) Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging examination results. Radiology 224:203–210PubMed

44.

Mullerad M et al (2004) Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology 232:140–146PubMed

45.

Perrotti M, Kaufman RP, Jenning TA, Thaler HT, Soloway SM, Rifkin MD, Fisher H (1996) Endorectal coil magnetic resonance imaging in clinically localized prostate cancer: Is it accurate? J Urol 156:106–109CrossRefPubMed

46.

Werner-Wasik M, Whittington R, Malkowicz SB, Corn BW, Arger P, Reisinger S, Langlotz C, Alexander A, D’Amico AV, Hyslop T. Gomella L, Brownstein K, Wein AJ (1997) Prostate imaging may not be necessary in nonpalpable carcinoma of the prostate. Urology 50:385–389CrossRefPubMed

47.

Thornbury JR, Ornstein DK, Choyke PL, Langlotz CP, Weinreb JC (2001) Prostate cancer: What is the future role for imaging? Am J Roentgenol 176:17–22

48.

Liney GP, Turnbull LW, Knowles AJ (1999) In vivo magnetic resonance spectroscopy and dynamic contrast enhanced imaging of the prostate gland. NMR Biomed 12:39–44CrossRefPubMed

49.

Jager GJ, Ruijter ETG, Van de Kaa CA, de la Rosette JJMCH, Oosterhof GON, Thornbury JR, Ruijs SHJ, Barentsz JO (1997) Dynamic Turboflash subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology 203:645–652PubMed

50.

Rouvière O, Raudrant A, Ecochard R, Colin-Pangaud P, Pasquiou C, Bouvier R, Maréchal JM, Lyonnet D (2003) Characterization of time-enhancement curves of benign and malignant prostate tissue at dynamic MR imaging. Eur Radiol 13:931–942PubMed

51.

Barentsz JO, Engelbrecht M, Jager GJ, Witjes JA, de LaRosette J, van der Sanden BPJ, Huisman HJ, Heerschap A (1999) Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. J Magn Reson Imaging 10:295–304

52.

Oyen RH (2003) Dynamic contrast-enhanced MRI of the prostate: Is this the way to proceed for characterization of prostatic carcinoma? Eur Radiol 13:921–924PubMed

53.

Engelbrecht MR, Huisman H, Laheij RJF, Jager GJ, Van leenders GJLH, Hulsbergen-Van De Kaa CA, de la Rosette J, Blickman JG, Barentsz JO (2003) Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 229:248–254PubMed

54.

Kiessling F, Lichy M, Grobholz R, Heilmann M, Farhan N, Michel MS, Trojan L, Ederle J, Abel U, Kauczor HU, Semmler W, Delorme S (2004) Simple models improve the discrimination of prostate cancers from the peripheral gland by T1-weighted dynamic MRI. Eur Radiol 14:1793–1801PubMed

55.

Schlemmer HP, Merkle J, Grobholz R, Jaeger T, Michel MS, Werner A, Rabe J, Van Kaick G (2004) Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol 14:309–317CrossRefPubMed

56.

Van Dorsten FA, Van der Graaf M, Engelbrecht MRW, Van Leenders GJLH, Verhofstad A, Rijpkema M, de la Rosette J, Barentsz JO, Heerschap A (2004) Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 20:279–287CrossRefPubMed

57.

Buckley DL, Roberts C, Parker GJM, Logue JP, Hutchinson CE (2004) Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging: initial experience. Radiology 233:709–715PubMed

58.

Padhani AR, Gapinski CJ, Macvicar DA, Parker GJ, Suckling J, Revell PB, Leach MO, Dearnaley DP, Husband JE (2000) Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumor stage, histological grade and PSA. Clin Radiol 55:99–109CrossRefPubMed

59.

Turnbull LW, Buckley DL, Turnbull LS, Liney GP, Knowles AJ (1999) Differentiation of prostatic carcinoma and benign prostatic hyperplasia: correlation between dynamic Gd-DTPA-ennhanced MR imaging and histopathology. J Magn Reson Imaging 9:311–316CrossRefPubMed

60.

Ogura K, Maekawa S, Okubo K, Aoki Y, Okada T, Oda K, Watanabe Y, Tsukayama C, Arai Y (2001) Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: correlation with histopathologic results. Urology 57:721–726CrossRefPubMed

61.

Preziosi P, Orlacchio A, Di Giambattista G, Di Renzi P, Bortolotti L, Fabiano A, Cruciani E, Pasqualetti P (2003) Enhancement patterns of prostate cancer in dynamic MRI. Eur Radiol 13:925–930PubMed

62.

Huisman HJ, Engelbrecht MR, Barentsz JO (2001) Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate. J Magn Reson Imaging 13:607–614CrossRefPubMed

63.

Tanaka N, Samma S, Joko M, Akiyama T, Takewa M, Kitano S, Okajima E (1999) Diagnostic usefulness of endorectal magnetic resonance imaging with dynamic contrast-enhancement in patients with localized prostate cancer: mapping studies with biopsy specimens. Int J Urol 6:593–599CrossRefPubMed

64.

Sosna J, Rofsky NM, Gaston SM, DeWolf WC, Lenkinski RE (2003) Determination of prostate volume at 3-Tesla using an external phased-array coil: comparison to pathologic specimens. Acad Radiol 10:846–853

65.

Sosna J, Pedrosa I, DeWolf WC, Mahallati H, Lenkinski RE, Rofsky NM (2004) MR imaging of the Prostate at 3 Tesla: comparison of an external phased-array coil to imaging with an endorectal coil at 1.5 Tesla. Acad Radiol 11:857–862CrossRefPubMed

66.

Bloch BN, Rofsky NM, Baroni RH, Marquis RP, Pedrosa I, Lenkinski RE (2004) 3 Tesla magnetic resonance imaging of the prostate with combined pelvic phased-array and endorectal coils: initial experience. Acad Radiol 11:863–867CrossRefPubMed

67.

Fütterer JJ, Scheenen TWJ, Huisman HJ, Klomp DWJ, Van Dorsten FA, Husbergen-Van de Kaa CA, Witjes JA? Heerschap A, Barentsz JO (2004) Initial experience of 3 Tesla endorectal coil magnetic resonance imaging and H-spectroscopic imaging of the prostate. Invest Radiol 39:671–680CrossRefPubMed

68.

Heijmink SW, Fütterer JJ, Scheenen TW, Jager GJ, Hulsbergen-Van de Kaa CA, Witjes JA, Barentsz JO (2005) Local staging of prostate cancer by T2-weighted imaging with an endorectal coil at 3 T. Proc Int Soc Magn Reson Med 13:271

69.

Bartha R, Drost DJ, Menon RS, Williamson PC (2000) Comparison of the quantification precision of human short echo time H Spectroscopy at 1.5 and 4.0 Tesla. Magn Reson Med 44:185–192CrossRefPubMed

70.

Barker PB, Hearshen DO, Boska MD (2001) Single-voxel proton MRS of the human brain at 1.5 T and 3.0 T. Magn Reson Med 45:765–769CrossRefPubMed

71.

Scheenen TWJ, Gambarota G, Weiland E, Klomp DWJ, Fütterer JJ, Barentsz JO, Heerschap A (2005) Optimal timing for in vivo H-MR spectroscopic imaging of the human prostate at 3 T. Magn Reson Med 53:1268–1274CrossRefPubMed

72.

Heerschap A, Jager GJ, Van Der Graaf M, Barentsz JO, Juijs SH (1997) Proton MR spectroscopy of the normal human prostate with an endorectal coil and a double spin-echo pulse sequence. Magn Reson Med 37:204–213PubMed

73.

Lowry M, Liney GP, Turnbull LW, Manton DJ, Blackband SJ, Horsman A (1996) Quantification of citrate concentration in the prostate by proton magnetic resonance spectroscopy: zonal and age-related differences. Magn Reson Med 36:352–358PubMed

74.

Kim DH, Margolis D, Xing L, Daniel B, Spielman D (2005) In vivo prostate magnetic resonance spectroscopic imaging using two-dimensional J-Resolved PRESS at 3 T. Magn Reson Med 53:1177–1182CrossRefPubMed

75.

Van der Graaf M, Van den Boogert HJ, Jager GJ, Barentsz JO, Heerschap A (1999) Human prostate: multisection proton MR spectroscopic imaging with a single spin-echo sequence-preliminary experience. Radiology 213:919–925PubMed

76.

Vigneron DB, Chen AP, Cunningham CH, Xu D, Hurd RE, Sailasuta N, Pauly JM, Nelson SJ, Kurhanewicz J (2004) High resolution 3D MR spectroscopic imaging and resolved MRS of the prostate at 3 Tesla. Proceedings of the 12th annual meeting of ISMRM, May 2004, Kyoto, Japan, pp 386

77.

Trabesinger AH, Meier D, Dydak U, Lamerichs R, Boesiger P (2003) Optimizing citrate detection at 3 Tesla. Proceedings of the 11th annual meeting of ISMRM, July 2003, Toronto, Canada, pp 760

78.

Cunningham CH, Vigneron DB, Marjanska M, Chen AP, Xu D, Hurd RE, Kurhanewicz J, Garwood M, Pauly JM (2005) Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T. Magn Reson Med 53:1033–1039CrossRefPubMed

79.

Chen AP, Cunningham CH, Xu D, Hurd RE, Coakley FV, Pauly J, Kurhanewicz J, Vigneron DB (2005) 3 Tesla high resolution 3D MR spectroscopic imaging of the prostate with a MLEV-PRESS sequence. Proc Int Soc Magn Reson Med 13:261

80.

Misic GJ, Feo DC, Barentsz JO, Scheenen TW, Klomp DW, Fütterer J, Heijmink SW, Callen DR, Monski WJ (2005) High performance ecoils and interfaces for 3.0 Tesla prostate imaging and spectroscopy. Proc Int Soc Magn Reson Med 13:939

81.

Ramachandran M, Venook RD, DiCarlo JC, Vidarsson L, Hargreaves BA, Connolly SM (2005) A low-noise, susceptibility-matched solution for endorectal imaging of the prostate. Proc Int Soc Magn Reson Med 13:1948

82.

Coakley FV, Qayyum A, Kurhanewicz J (2003) Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol 170:S69–S76CrossRefPubMed

Titel: Prostate MR imaging at high-field strength: evolution or revolution?
verfasst von: Olivier Rouvière
Robert P. Hartman
Denis Lyonnet
Publikationsdatum: 01.02.2006
Verlag: Springer-Verlag
Erschienen in: European Radiology / Ausgabe 2/2006
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-005-2893-8

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Prostate MR imaging at high-field strength: evolution or revolution?

Abstract

Neu im Fachgebiet Radiologie

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Klinikreform soll zehntausende Menschenleben retten

Darf man die Behandlung eines Neonazis ablehnen?

Update Radiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2006

Automatic determination of minimal cardiac motion phases for computed tomography imaging: initial experience

3D CT protocol in the assessment of the esophageal neoplastic lesions: can it improve TNM staging?

First performance evaluation of a dual-source CT (DSCT) system

Left ventricular function studied with MDCT

Endovascular gamma irradiation for the prevention restenosis after angioplasty of femoropopliteal de novo stenoses

Cervical cancer: MR imaging findings before, during, and after radiation therapy

Neu im Fachgebiet Radiologie

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Klinikreform soll zehntausende Menschenleben retten

Darf man die Behandlung eines Neonazis ablehnen?

Update Radiologie